2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
78
Neoplasms
69
Prostatic Neoplasms
51
Colorectal Neoplasms
45
Lung Neoplasms
39
Carcinoma, Non-Small-Cell Lung
28
Hematologic Neoplasms
22
Pancreatic Neoplasms
21
Neoplasm Metastasis
20
Head and Neck Neoplasms
20
Urinary Bladder Neoplasms
15
Ovarian Neoplasms
15
Multiple Myeloma
15
Stomach Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Motor Activity
11
Leukemia, Myeloid, Acute
11
Glioblastoma
10
Uterine Cervical Neoplasms
9
Triple Negative Breast Neoplasms
9
Gastrointestinal Neoplasms
9
Colonic Neoplasms
9
Melanoma
8
Hematopoietic and Lymphatic System Neoplasm
8
Glioma
8
Esophageal Neoplasms
8
Carcinoma, Renal Cell
8
COVID-19
8
Anxiety Disorders
8
Anatomic Stage I Breast Cancer AJCC v8
8
Interventions
trametinib
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Progressive Metastatic Castrate Resistant Prostate Cancer
×
Standard of Care
×
Clear all
NCT07206056
2026-06-03
TulmiSTAR-01
Novartis
Phase 1/2
Recruiting
188 enrolled